Monday, June 19, 2023 Daily Archives

J&J eyes internal and external expansions to support Carvykti rollout

by

In a bid to move Carvykti further up the line of treatment, J&J is scaling up its external and internal capacity. In March 2022, the US Food and Drug Administration (FDA) granted authorization for Carvykti (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Johnson & Johnson (J&J) and its partner Legend Biotech, to treat white blood cell cancer. The CAR-T therapy is currently only allowed as a fifth-line therapy. However, as part of its clinical development strategy and hope…

June 19, 2023

Sartorius lowers 2023 forecast as COVID hangover drags on

by

Sales and margins will be lower than expected due to post-pandemic reductions in inventories, but Sartorius believes this a temporary blip in the highly positive biopharma space. It was October 2022 when bioprocess vendor Sartorius warned of a sales growth comedown after demand during the COVID-19 pandemic drove two years of unprecedented growth. And while the realization of a “swift normalization of demand” was factored into the firm’s 2023 forecasts, six months in and Sartorius has lowered its expectations for…

June 19, 2023

Cytiva adds Culture bioreactors to tackle scaling bottlenecks

by

The combination of Culture Bio’s single-use 250 mL bioreactor to Cytiva’s web-based Bioreactor Scaler Tool aims to de-risk scaling activities for biomanufacturers. Under terms of the collaboration, the Cytiva web-based Bioreactor Scaler Tool now includes Culture Bio’s 250 mL bioreactor vessel. “Combining our technologies makes it easier and more predictable for customers to scale processes between Culture’s high-throughput, development-scale platform into Cytiva’s commercial-scale bioreactor platform,” the companies told BioProcess Insider. “Both systems leverage web- and cloud-based technologies. Process scientists can…

June 19, 2023